NEW YORK (GenomeWeb News) - Compugen said this week that Anat Cohen-Dayag and Martin Gerstel will serve as co-CEOs of the company. Cohen-Dayag started with the company in 2002, and she has served as VP for diagnostic biomarkers and drug targets. Before starting at Compugen, she was head of R&D at Mindsense Biosystems.
Gerstel began at Compugen in 1997 as chairman and was appointed president and CEO earlier this year. Before joining Compugen, Gerstel was co-chairman and CEO of ALZA Corporation and a director of the Pharmaceutical Research and Manufacturers of America.